Patents by Inventor Jian-Feng Lu
Jian-Feng Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11942324Abstract: A method of promoting adhesion between a dielectric layer of a semiconductor device and a metal fill deposited within a trench in the dielectric layer, including performing an ion implantation process wherein an ion beam formed of an ionized dopant species is directed into the trench at an acute angle relative to a top surface of the dielectric layer to form an implantation layer in a sidewall of the trench, and depositing a metal fill in the trench atop an underlying bottom metal layer, wherein the metal fill adheres to the sidewall.Type: GrantFiled: June 10, 2020Date of Patent: March 26, 2024Assignee: Applied Materials, Inc.Inventors: Qintao Zhang, Jun-Feng Lu, Ting Cai, Ma Ning, Weiye He, Jian Kang
-
Patent number: 11845801Abstract: Provided herein are IL-15 cytokine prodrugs and methods of making and using thereof.Type: GrantFiled: June 12, 2020Date of Patent: December 19, 2023Assignee: ASKGENE PHARMA, INC.Inventors: Yuefeng Lu, Chunxiao Yu, Jian-Feng Lu
-
Publication number: 20230303714Abstract: Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.Type: ApplicationFiled: November 21, 2022Publication date: September 28, 2023Applicants: AskGene Pharma Inc., Jiangsu AoSaiKang Pharmaceutical Co., Ltd.Inventors: Yuefeng Lu, Kurt Shanebeck, Lu Li, Lei Liu, Shiwen Zhang, Lan Yang, Jian-Feng Lu
-
Patent number: 11746147Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.Type: GrantFiled: January 13, 2020Date of Patent: September 5, 2023Assignees: AskGene Pharma Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.Inventors: Yuefeng Lu, Jian-Feng Lu
-
Publication number: 20230212311Abstract: The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.Type: ApplicationFiled: June 15, 2022Publication date: July 6, 2023Applicant: Genentech, Inc.Inventors: DAVID E. ALLISON, RENE BRUNO, JIAN-FENG LU, CHEE M. NG
-
Publication number: 20230135521Abstract: The present specification discloses a pharmaceutical composition or stable aqueous formulations for erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, and methods and uses of erythropoietin receptor agonists and compositions. The present specification further discloses medicaments for treating an anemia in non-human mammals such as cats.Type: ApplicationFiled: April 22, 2019Publication date: May 4, 2023Applicant: AskGene Pharma Inc.Inventors: Yuefeng Lu, Jian-Feng Lu, Lu Li, Ming Li
-
Publication number: 20230108562Abstract: Provided herein are prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer, autoimmune or an infectious disease.Type: ApplicationFiled: January 11, 2021Publication date: April 6, 2023Applicant: ASKGENE PHARMA, INC.Inventors: Yuefeng LU, Chunxiao YU, Jian-Feng LU, Liqin LIU
-
Patent number: 11505618Abstract: Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.Type: GrantFiled: July 18, 2019Date of Patent: November 22, 2022Assignees: AskGene Pharma Inc., Jiangsu AoSaiKang Pharmaceutical Co., Ltd.Inventors: Yuefeng Lu, Kurt Shanebeck, Lu Li, Lei Liu, Shiwen Zhang, Lan Yang, Jian-Feng Lu
-
Publication number: 20220041705Abstract: The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).Type: ApplicationFiled: July 13, 2021Publication date: February 10, 2022Applicant: AskGene Pharma Inc.Inventors: Yuefeng Lu, Jian-Feng Lu
-
Publication number: 20210260163Abstract: Provided herein are cytokine muteins and cytokine prodrugs and methods of making and using thereof.Type: ApplicationFiled: March 11, 2019Publication date: August 26, 2021Applicant: AskGene Pharma, Inc.Inventors: Chunxiao YU, Yuefeng LU, Jian-Feng LU
-
Patent number: 11059885Abstract: The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).Type: GrantFiled: April 10, 2019Date of Patent: July 13, 2021Assignee: AskGene Pharma Inc.Inventors: Yuefeng Lu, Jian-Feng Lu
-
Publication number: 20200392235Abstract: Provided herein are IL-15 cytokine prodrugs and methods of making and using thereof.Type: ApplicationFiled: June 12, 2020Publication date: December 17, 2020Applicant: ASKGENE PHARMA, INC.Inventors: Yuefeng LU, Chunxiao YU, Jian-Feng LU
-
Publication number: 20200239595Abstract: The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.Type: ApplicationFiled: December 10, 2019Publication date: July 30, 2020Applicant: Genentech, Inc.Inventors: DAVID E. ALLISON, RENE BRUNO, JIAN-FENG LU, CHEE M. NG
-
Patent number: 10654922Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.Type: GrantFiled: May 11, 2017Date of Patent: May 19, 2020Assignees: AskGene Pharma Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.Inventors: Yuefeng Lu, Jian-Feng Lu
-
Publication number: 20200131260Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.Type: ApplicationFiled: January 13, 2020Publication date: April 30, 2020Applicants: AskGene Pharma Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.Inventors: Yuefeng Lu, Jian-Feng Lu
-
Publication number: 20200102381Abstract: The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).Type: ApplicationFiled: April 10, 2019Publication date: April 2, 2020Applicant: AskGene Pharma Inc.Inventors: Yuefeng Lu, Jian-Feng Lu
-
Publication number: 20200040101Abstract: Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.Type: ApplicationFiled: July 18, 2019Publication date: February 6, 2020Applicants: AskGene Pharma Inc., Jiangsu AoSaiKang Pharmaceutical Co., Ltd.Inventors: Yuefeng Lu, Kurt Shanebeck, Lu Li, Lei Liu, Shiwen Zhang, Lan Yang, Jian-Feng Lu
-
Publication number: 20190248858Abstract: The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.Type: ApplicationFiled: April 30, 2019Publication date: August 15, 2019Applicant: AskGene Pharma Inc.Inventors: Jian-Feng Lu, Yuefeng Lu, Aijun Wang, Donggou He, Kurt Shanebeck, Chen Yao
-
Patent number: 10287336Abstract: The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.Type: GrantFiled: September 17, 2015Date of Patent: May 14, 2019Assignee: AskGene Pharma, Inc.Inventors: Jian-Feng Lu, Yuefeng Lu, Aijun Wang, Donggou He, Kurt Shanebeck, Chen Yao
-
Publication number: 20190106494Abstract: The present invention relates to compositions and methods for immunotherapy of a subject afflicted with diseases such as cancer, an infectious disease, or a neurodegenerative disease, which methods comprise administering to the subject a composition comprising a therapeutically effective amount of an anti-PD-L1 antibody or portion thereof that potentiates an endogenous immune response, either stimulating the activation of the endogenous response or inhibiting the suppression of the endogenous response.Type: ApplicationFiled: August 23, 2018Publication date: April 11, 2019Applicants: AskGene Pharma Inc., Jiangsu AoSaiKang Pharmaceutical Co., Ltd.Inventors: Aijun Wang, Kurt Shanebeck, Donggou He, Chen Yao, Lu Li, Fang Xia, Yuefeng Lu, Jian-Feng Lu, Lan Yang